NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc.

NRXP·NASDAQ

$4.05

-12%
HealthcareBiotechnology

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

At a Glance

Live Snapshot
Market Cap$70.01M
EPS-1.3400
P/E Ratio-3.02
Earnings Date08/17/2026

nrxp

Long Term Debt

Last Annual Value

315.00K

3-Year CAGR

-52%

5-Year CAGR

-10%

10-Year CAGR

%

NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. Competitors Analysis of Long Term Debt

NRXP · NASDAQ
CompanyLong Term Debt
CAGR 3Y
CAGR 5Y
CAGR 10Y
315.00K
N/AN/AN/A 
356.00K
N/A-47.3%N/A
150.00K
0.0%-38.1%N/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
MNOV logo
MediciNova, Inc.
NASDAQ:MNOV
0.00
N/AN/AN/A
0.00
N/AN/AN/A
1.54M
N/AN/AN/A
0.00
N/AN/AN/A
188.80B
N/A604.4%211.0%
0.00
N/AN/AN/A
NRx Pharmaceuticals, Inc.

NRx Pharmaceuticals, Inc. Fair Value Envelope

NRXP · NASDAQ

Our analysis suggests that NRXP has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.05, this represents a potential HIDDEN relative to our calculated worth for NRx Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $4.05